DB:5NR

Stock Analysis Report

Executive Summary

Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide.


Snowflake Analysis

Limited growth with imperfect balance sheet.

Share Price & News

How has Nanobiotix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 5NR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

5.9%

5NR

3.3%

DE Biotechs

2.2%

DE Market


1 Year Return

-50.3%

5NR

-11.2%

DE Biotechs

-17.2%

DE Market

Return vs Industry: 5NR underperformed the German Biotechs industry which returned -11.2% over the past year.

Return vs Market: 5NR underperformed the German Market which returned -17.2% over the past year.


Shareholder returns

5NRIndustryMarket
7 Day5.9%3.3%2.2%
30 Day-23.1%-6.5%-15.7%
90 Day-33.9%-23.1%-24.0%
1 Year-50.3%-50.3%-11.0%-11.2%-14.9%-17.2%
3 Year-69.3%-69.3%14.9%13.6%-16.4%-23.3%
5 Year-70.5%-70.5%-8.0%-10.3%-16.5%-27.8%

Price Volatility Vs. Market

How volatile is Nanobiotix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Nanobiotix undervalued compared to its fair value and its price relative to the market?

6.84x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: 5NR (€5.48) is trading above our estimate of fair value (€0.08)

Significantly Below Fair Value: 5NR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 5NR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 5NR is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 5NR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 5NR is overvalued based on its PB Ratio (6.8x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Nanobiotix forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-5.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5NR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 5NR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 5NR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 5NR's revenue (52.1% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: 5NR's revenue (52.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 5NR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Nanobiotix performed over the past 5 years?

-26.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 5NR is currently unprofitable.

Growing Profit Margin: 5NR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 5NR is unprofitable, and losses have increased over the past 5 years at a rate of -26.5% per year.

Accelerating Growth: Unable to compare 5NR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5NR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: 5NR has a negative Return on Equity (-245.56%), as it is currently unprofitable.


Next Steps

Financial Health

How is Nanobiotix's financial position?


Financial Position Analysis

Short Term Liabilities: 5NR's short term assets (€59.8M) exceed its short term liabilities (€12.4M).

Long Term Liabilities: 5NR's short term assets (€59.8M) exceed its long term liabilities (€42.2M).


Debt to Equity History and Analysis

Debt Level: 5NR's debt to equity ratio (178.7%) is considered high.

Reducing Debt: 5NR's debt to equity ratio has increased from 7.7% to 178.7% over the past 5 years.


Balance Sheet

Inventory Level: 5NR has a low level of unsold assets or inventory.

Debt Coverage by Assets: 5NR's debt is covered by short term assets (assets are 1.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 5NR has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 5NR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Nanobiotix's current dividend yield, its reliability and sustainability?

0.12%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 5NR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 5NR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 5NR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 5NR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 5NR's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Laurent Lévy (46yo)

no data

Tenure

€1,427,080

Compensation

Mr. Laurent Lévy, Ph.D. serves as the President of the Executive Board and Chief Executive Officer of Nanobiotix SA at Valbiotis SAS. Mr. Lévy co-founded Nanobiotix SA in 2003. Mr. Lévy has a thorough unde ...


CEO Compensation Analysis

Compensation vs Market: Laurent's total compensation ($USD1.57M) is above average for companies of similar size in the German market ($USD701.62K).

Compensation vs Earnings: Laurent's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Laurent Lévy
Co-Founderno data€1.43m3.27% 4.6m
Philippe Mauberna
Chief Financial & Administrative Officer and Member of the Executive Boardno data€949.41kno data
Elsa Borghi
Head of Innovation & Drug Discoveryno data€723.42k0.44% 618.5k
Para Prasad
Co-Founder and Member of Scientific Boardno datano datano data
Earl Bergey
Co-Founder17.17yrsno datano data
Alain Dostie
Chief Operating Officer3yrsno datano data
Anne-Juliette Hermant
Chief People Officer (CPO) & Member of Executive Board0.67yrno datano data
Noël Kurdi
Director of Investor Relations3.42yrsno datano data
Brandon Owens
VP of Strategic Marketing & Corporate Communicationno datano datano data
Sarah Gaubert
Head of Communication & Public Affairs Departmentno datano datano data

3.4yrs

Average Tenure

64yo

Average Age

Experienced Management: 5NR's management team is considered experienced (3.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Para Prasad
Co-Founder and Member of Scientific Boardno datano datano data
Enno Spillner
Independent Member of Supervisory Board6.17yrs€14.29kno data
Christophe Douat
Member of Supervisory Board9.17yrs€10.71kno data
Michel Marty
Member of Scientific Boardno datano datano data
Laurent Condomine
Independent Chairman of Supervisory Boardno data€21.43kno data
Jean Claude
Member of Scientific Boardno datano datano data
Alain Herrera
Member of Supervisory Board6.67yrs€70.71kno data
Anne-Marie Graffin
Independent Vice Chairman of the Supervisory Boardno data€12.86kno data

6.7yrs

Average Tenure

58yo

Average Age

Experienced Board: 5NR's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.


Top Shareholders

Company Information

Nanobiotix S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nanobiotix S.A.
  • Ticker: 5NR
  • Exchange: DB
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €142.140m
  • Shares outstanding: 22.40m
  • Website: https://www.nanobiotix.com

Number of Employees


Location

  • Nanobiotix S.A.
  • 60 rue de Wattignies
  • Paris
  • Ile-de-France
  • 75012
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NANOENXTPA (Euronext Paris)YesOrdinary SharesFREUROct 2012
0QAVLSE (London Stock Exchange)YesOrdinary SharesGBEUROct 2012
NANOPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEUROct 2012
5NRDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2012
NNBX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2012

Biography

Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer; BTXR3 nanoparticles + gel; and NBTX-IV, an aqueous suspension for brain metastasis and advanced stage tumors. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 23:58
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.